PROTEIN BINDING INSULIN-LIKE GROWTH FACTOR, PHARMACEUTICAL COMPOSITION

摘要

FIELD: chemistry of proteins, pharmacy. SUBSTANCE: invention relates to protein that can be used for diagnosis of bone tissue metabolism disturbance as a component of pharmaceutical composition for treatment of patients with osteoporosis. Protein has molecular mass 29 kDa, it binds hydroxylapatite in the presence of 4 M guanidine hydrochloride and insulin-like growth factor-1 at the range of concentrations 10-8-10 M. N-Terminal amino acid sequence of this protein is the following: Leu-Gly-Phe-Phe-Val-X-Val-Glu-Pro-Asp-Asp-Lys-Ala-Ala-Leu where X is not determined. EFFECT: enhanced effectiveness of protein factor. 3 cl, 4 dwg , 4 tblt